|
|
| Line 8: |
Line 8: |
| | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8p77 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8p77 OCA], [https://pdbe.org/8p77 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8p77 RCSB], [https://www.ebi.ac.uk/pdbsum/8p77 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8p77 ProSAT]</span></td></tr> | | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8p77 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8p77 OCA], [https://pdbe.org/8p77 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8p77 RCSB], [https://www.ebi.ac.uk/pdbsum/8p77 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8p77 ProSAT]</span></td></tr> |
| | </table> | | </table> |
| - | == Function == | + | <div style="background-color:#fffaf0;"> |
| - | [https://www.uniprot.org/uniprot/CDK7_HUMAN CDK7_HUMAN] Serine/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription. Cyclin-dependent kinases (CDKs) are activated by the binding to a cyclin and mediate the progression through the cell cycle. Each different complex controls a specific transition between 2 subsequent phases in the cell cycle. Required for both activation and complex formation of CDK1/cyclin-B during G2-M transition, and for activation of CDK2/cyclins during G1-S transition (but not complex formation). CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation, thus regulating cell cycle progression. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminus domain (CTD) of its large subunit (POLR2A), allowing its escape from the promoter and elongation of the transcripts. Phosphorylation of POLR2A in complex with DNA promotes transcription initiation by triggering dissociation from DNA. Its expression and activity are constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 activation by phosphorylation, but is inactivated in turn by p53/TP53; this feedback loop may lead to an arrest of the cell cycle and of the transcription, helping in cell recovery, or to apoptosis. Required for DNA-bound peptides-mediated transcription and cellular growth inhibition.<ref>PMID:9372954</ref> <ref>PMID:9840937</ref> <ref>PMID:10024882</ref> <ref>PMID:11113184</ref> <ref>PMID:16327805</ref> <ref>PMID:17386261</ref> <ref>PMID:17373709</ref> <ref>PMID:17901130</ref> <ref>PMID:19450536</ref> <ref>PMID:19015234</ref> <ref>PMID:19667075</ref> <ref>PMID:19136461</ref> <ref>PMID:19071173</ref> <ref>PMID:20360007</ref>
| + | == Publication Abstract from PubMed == |
| | + | Rational design of next-generation therapeutics can be facilitated by high-resolution structures of drug targets bound to small-molecule inhibitors. However, application of structure-based methods to macromolecules refractory to crystallization has been hampered by the often-limiting resolution and throughput of cryogenic electron microscopy (cryo-EM). Here, we use high-resolution cryo-EM to determine structures of the CDK-activating kinase, a master regulator of cell growth and division, in its free and nucleotide-bound states and in complex with 15 inhibitors at up to 1.8 A resolution. Our structures provide detailed insight into inhibitor interactions and networks of water molecules in the active site of cyclin-dependent kinase 7 and provide insights into the mechanisms contributing to inhibitor selectivity, thereby providing the basis for rational design of next-generation therapeutics. These results establish a methodological framework for the use of high-resolution cryo-EM in structure-based drug design. |
| | + | |
| | + | High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design.,Cushing VI, Koh AF, Feng J, Jurgaityte K, Bondke A, Kroll SHB, Barbazanges M, Scheiper B, Bahl AK, Barrett AGM, Ali S, Kotecha A, Greber BJ Nat Commun. 2024 Mar 13;15(1):2265. doi: 10.1038/s41467-024-46375-9. PMID:38480681<ref>PMID:38480681</ref> |
| | + | |
| | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> |
| | + | </div> |
| | + | <div class="pdbe-citations 8p77" style="background-color:#fffaf0;"></div> |
| | == References == | | == References == |
| | <references/> | | <references/> |
| Structural highlights
Publication Abstract from PubMed
Rational design of next-generation therapeutics can be facilitated by high-resolution structures of drug targets bound to small-molecule inhibitors. However, application of structure-based methods to macromolecules refractory to crystallization has been hampered by the often-limiting resolution and throughput of cryogenic electron microscopy (cryo-EM). Here, we use high-resolution cryo-EM to determine structures of the CDK-activating kinase, a master regulator of cell growth and division, in its free and nucleotide-bound states and in complex with 15 inhibitors at up to 1.8 A resolution. Our structures provide detailed insight into inhibitor interactions and networks of water molecules in the active site of cyclin-dependent kinase 7 and provide insights into the mechanisms contributing to inhibitor selectivity, thereby providing the basis for rational design of next-generation therapeutics. These results establish a methodological framework for the use of high-resolution cryo-EM in structure-based drug design.
High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design.,Cushing VI, Koh AF, Feng J, Jurgaityte K, Bondke A, Kroll SHB, Barbazanges M, Scheiper B, Bahl AK, Barrett AGM, Ali S, Kotecha A, Greber BJ Nat Commun. 2024 Mar 13;15(1):2265. doi: 10.1038/s41467-024-46375-9. PMID:38480681[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Cushing VI, Koh AF, Feng J, Jurgaityte K, Bondke A, Kroll SHB, Barbazanges M, Scheiper B, Bahl AK, Barrett AGM, Ali S, Kotecha A, Greber BJ. High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design. Nat Commun. 2024 Mar 13;15(1):2265. PMID:38480681 doi:10.1038/s41467-024-46375-9
|
